IFN-γ blockade with AMG811, a human monoclonal antibody against IFN-γ, initially showed some promise in SLE where treatment of stable SLE patients, led to dose dependent modulation of genes associated with IFN-γ signalling and reduction in serum levels of CXCL10, a key chemokine associated with SLE disease activity [190]. This evidence concerns the gene CXCL10 and systemic lupus erythematosus.